netFormulary
 Report : A-Z NHS England items in Formulary 20/09/2020 02:33:46
[Back]
 
Section Status NHS England Name
08.01.05 Formulary MHS England Abemaciclib tabs 
08.03.04.02 Formulary MHS England Abiraterone tabs 
11.99.99.99 Formulary MHS England Adalimumab injection uveitis
13.05.03 Formulary MHS England Adalimumab injection Hidradenitis suppurativa
08.01.05 Formulary MHS England Afatinib tabs 
08.02.04 Formulary MHS England Aldesleukin injection 
08.01.05 Formulary MHS England Alectinib caps 
08.02.03 Formulary MHS England Alemtuzumab injection multiple sclerosis
10.01.03 Formulary MHS England Anakinra injection Adult-Onset Still's Disease
08.02.02 Formulary MHS England Antithymocyte immunoglobulin injection (ATG) 
08.02.02 Formulary MHS England Antithymocyte immunoglobulin injection (ATG) 
08.01.05 Formulary MHS England Arsenic trioxide injection 
08.01.05 Formulary MHS England Atezolizumab injection lung cancer indications
08.01.05 Formulary MHS England Atezolizumab injection breast cancer indications
08.01.05 Formulary MHS England Atezolizumab injection urothelial cancer indications
08.01.05 Formulary MHS England Avelumab injection  
08.01.05 Formulary MHS England Axicabtagene ciloleucel cells dispersion for infusion 
08.01.05 Formulary MHS England Axitinib tabs 
08.01.03 Restricted Use MHS England Azacitidine injection 
08.02.01 Formulary MHS England Azathioprine tabs liver transplant
08.02.01 Formulary MHS England Azathioprine tabs, injection renal transplant
08.02.02 Formulary MHS England Basiliximab injection 
05.01.09 Formulary MHS England Bedaquiline tabs Sirturo®
10.01.03 Restricted Use MHS England Belimumab injection 
08.01.01 Formulary MHS England Bendamustine injection 
03.04.02 Formulary MHS England Benralizumab injection 
08.01.05 Formulary MHS England Bevacizumab injection neurofibromatosis type 2 - off-label
08.01.05 Formulary MHS England Bevacizumab injection licensed use
08.01.05 Formulary MHS England Binimetinib tabs 
08.02.03 Formulary MHS England Blinatumomab injection 
08.01.05 Formulary MHS England Bortezomib injection 
02.05.01 Restricted Use MHS England Bosentan tabs digital ulcer disease - off-label
08.01.05 Formulary MHS England Bosutinib tabs 
08.01.05 Formulary MHS England Brentuximab injection 
08.01.05 Formulary MHS England Brigatinib tabs 
03.04.03 Formulary MHS England C1 esterase inhibitor injection 
08.01.05 Formulary MHS England Cabazitaxel injection 
08.01.05 Formulary MHS England Cabozantinib caps Cometriq - thyroid cancer
08.01.05 Formulary MHS England Cabozantinib tablets Cabometyx - renal carcinoma
04.06 Formulary MHS England Cannabidiol solution Epidyolex
08.01.05 Formulary MHS England Carfilzomib injection  
08.01.05 Formulary MHS England Cemiplimab injection  
08.01.05 Formulary MHS England Ceritinib caps 
08.01.05 Formulary MHS England Cetuximab injection colorectal cancer
08.01.05 Formulary MHS England Cetuximab injection head and neck cancer
01.09.01 Formulary MHS England Chenodeoxycholic acid capsules 
01.09.01 Formulary MHS England Cholic acid capsules 
08.02.02 Formulary MHS England Ciclosporin caps, oral liquid, injection renal transplant
09.05.01.02 Restricted Use MHS England Cinacalcet tablets primary hyperparathyroidism
08.02.04 Formulary MHS England Cladribine tabs multiple sclerosis
04.09.01 Formulary MHS England Co-careldopa intestinal gel Duodopa®
08.01.05 Formulary MHS England Crizotinib caps 
08.01.03 Formulary MHS England Cytarabine and daunorubicin (liposomal) injection Vyxeos®
08.01.05 Formulary MHS England Dabrafenib caps 
08.01.05 Formulary MHS England Dacomitinib caps 
08.02.04 Formulary MHS England Daratumumab injection 
08.01.05 Formulary MHS England Dasatinib tabs 
02.08.01 Formulary MHS England Defibrotide infusion 
05.01.09 Formulary MHS England Delamanid tabs Deltyba®
08.02.04 Formulary MHS England Dimethyl fumarate caps Tecfidera - multiple sclerosis
08.01.05 Formulary MHS England Docetaxel injection 
08.01.02 Formulary MHS England Doxorubicin hydrochloride pegylated liposomal injection 
08.01.05 Formulary MHS England Durvalumab injection 
09.01.03 Restricted Use MHS England Eculizumab injection C3 glomerulopathy post-kidney transplant
09.01.03 Formulary MHS England Eculizumab injection Atypical Haemolytic Uraemic Syndrome [aHUS]
03.07 Formulary MHS England Elexacaftor-tezacaftor-ivacaftor tabs 
09.01.03 Formulary MHS England Emicizumab injection 
08.01.05 Formulary MHS England Encorafenib caps 
08.03.04.02 Formulary MHS England Enzalutamide tabs 
05.03.03.02 Formulary MHS England Epclusa® tabs sofosbuvir and velpatasvir
08.01.05 Formulary MHS England Eribulin injection 
08.01.05 Formulary MHS England Erlotinib tabs 
09.05.01.02 Formulary MHS England Etelcalcetide injection 
08.01.05 Formulary MHS England Everolimus tabs neuroendocrine tumours
08.01.05 Formulary MHS England Everolimus tabs seizures associated with tuberous sclerosis complex
08.01.05 Formulary MHS England Everolimus tabs breast cancer
08.01.05 Formulary MHS England Everolimus tabs renal cancer
08.02.04 Formulary MHS England Fingolimod caps 
08.01.05 Formulary MHS England Gefitinib tabs 
08.02.03 Formulary MHS England Gemtuzumab ozogamicin infusion 
08.02.04 Formulary MHS England Glatiramer acetate injection 
08.01 Restricted Use MHS England Glucarpidase injection 
05.03.03.02 Formulary MHS England Harvoni® tabs sofosbuvir and ledipasvir
08.01.05 Formulary MHS England Ibrutinib caps 
03.04.03 Restricted Use MHS England Icatibant injection 
08.01.05 Formulary MHS England Idelalisib tabs 
02.05.01 Restricted Use MHS England Iloprost nebuliser solution  pulmonary hypertension
08.01.05 Formulary MHS England Imatinib tabs Graft vs Host Disease - off-label
08.01.05 Formulary MHS England Imatinib tabs licensed commissioned use
04.12 Formulary MHS England Infliximab injection Neurosarcoidosis off-label
08.01.05 Formulary MHS England Inotuzumab ozogamicin injection 
08.02.04 Formulary MHS England Interferon alfa-2a injection 
08.02.04 Formulary MHS England Interferon alfa-2b injection 
08.02.04 Formulary MHS England Interferon beta-1a injection multiple sclerosis
08.02.04 Formulary MHS England Interferon beta-1b injection multiple sclerosis
08.01.05 Formulary MHS England Ipilimumab injection 
05.02.01 Formulary MHS England Isavuconazole tabs, injection 
03.07 Formulary MHS England Ivacaftor tabs 
08.02.04 Formulary MHS England Ixazomib caps 
03.04.03 Formulary MHS England Lanadelumab injection 
08.03.04.03 Formulary MHS England Lanreotide injection 
08.02.04 Formulary MHS England Lenalidomide caps licensed use
08.01.05 Formulary MHS England Lenvatinib caps renal cancer - Kisplyx®
08.01.05 Formulary MHS England Lenvatinib caps thyroid cancer - Lenvima®
08.01.05 Formulary MHS England Lenvatinib caps hepatocellular carcinoma - Lenvima®
05.03.02.02 Formulary MHS England Letermovir tabs 
08.01.05 Formulary MHS England Lorlatinib tabs Non-small-cell lung cancer
03.07 Formulary MHS England Lumacaftor–ivacaftor tabs 
08.01.05 Formulary MHS England Lutetium (177Lu) oxodotreotide injection 
05.03.03.02 Formulary MHS England Maviret® tabs glecaprevir and pibrentasvir
10.02.02 Formulary MHS England Mexiletine caps congenital myotonia
08.01.05 Formulary MHS England Midostaurin caps 
08.02.01 Formulary MHS England Mycophenolate mofetil tabs, caps, suspension, injection liver transplant
08.02.01 Formulary MHS England Mycophenolate mofetil tabs, caps, suspension, injection renal transplant
08.02.01 Restricted Use MHS England Mycophenolate sodium tablets renal transplant
08.02.04 Restricted Use MHS England Natalizumab injection 
08.01.05 Formulary MHS England Neratinib tabs 
08.01.05 Formulary MHS England Nilotinib caps 
03.11 Formulary MHS England Nintedanib caps Ofev® - idiopathic pulmonary fibrosis
08.01.05 Formulary MHS England Nintedanib caps Vargatef® Non-small-cell lung cancer
08.01.05 Formulary MHS England Niraparib caps 
08.01.05 Formulary MHS England Nivolumab injection haematological and lung cancer
08.01.05 Formulary MHS England Nivolumab injection head and neck, renal and skin cancer
08.01.05 Formulary MHS England Nivolumab injection urothelial cancer
01.09.01 Formulary MHS England Obeticholic acid tabs 
08.02.03 Formulary MHS England Obinutuzumab injection 
08.02.04 Formulary MHS England Ocrelizumab injection 
08.03.04.03 Formulary MHS England Octreotide injection, depot injection 
08.02.03 Formulary MHS England Ofatumumab injection 
08.01.05 Formulary MHS England Olaparib tabs 
08.01.05 Formulary MHS England Osimertinib tabs 
08.01.05 Formulary MHS England Paclitaxel albumin injection Abraxane
08.01.05 Formulary MHS England Paclitaxel injection 
08.01.05 Formulary MHS England Palbociclib tabs 
08.01.05 Formulary MHS England Panitumumab injection 
08.01.05 Formulary MHS England Panobinostat caps 
08.03.04.03 Formulary MHS England Pasireotide injection 
08.01.05 Formulary MHS England Pazopanib tabs 
08.01.05 Formulary MHS England Pegaspargase injection 
05.03.03.01 Formulary MHS England Peginterferon alfa-2a injection 
08.02.04 Restricted Use MHS England Peginterferon alfa-2a injection 
08.02.04 Restricted Use MHS England Peginterferon alfa-2a injection 
08.02.04 Restricted Use MHS England Peginterferon alfa-2b injection chronic hep C
08.02.04 Formulary MHS England Peginterferon beta-1a injection 
06.05.01 Formulary MHS England Pegvisomant injection 
08.01.05 Formulary MHS England Pembrolizumab injection skin cancer indications
08.01.05 Formulary MHS England Pembrolizumab injection lymphoma and lung cancer indications
08.01.05 Formulary MHS England Pembrolizumab injection urothelial cancer indications
08.01.03 Formulary MHS England Pemetrexed injection 
08.01.05 Formulary MHS England Pertuzumab injection 
03.11 Formulary MHS England Pirfenidone caps 
08.01.02 Formulary MHS England Pixantrone injection 
09.01.07 Restricted Use MHS England Plerixafor injection 
08.02.04 Formulary MHS England Pomalidomide caps 
08.01.05 Formulary MHS England Ponatinib tabs 
03.04.03 Formulary MHS England Recombinant C1 esterase inhibitor injection Ruconest, Conestat Alpha
08.01.05 Formulary MHS England Regorafenib tabs gastrointestinal stromal tumours
08.01.05 Formulary MHS England Regorafenib tabs hepatocellular carcinoma
05.03 Formulary MHS England Remdesivir injection 
03.04.02 Formulary MHS England Reslizumab injection 
08.01.05 Formulary MHS England Ribociclib tabs 
08.02.03 Formulary MHS England Rituximab injection Graft vs Host Disease - off-label
08.02.03 Formulary MHS England Rituximab injection haematological malignancies
10.01.03 Restricted Use MHS England Rituximab injection rheumatology - off-label indications
10.01.03 Formulary MHS England Rituximab injection ANCA vasculitis
10.02.01 Formulary MHS England Rituximab injection myaesthenia gravis - off-label
08.02.03 Formulary MHS England Rituximab subcutaneous injection haematological malignancies
08.02.03 Formulary MHS England Rituxmab injection anti-NMDAR autoimmune encephalitis - off-label
08.01.05 Formulary MHS England Rucaparib tabs 
08.01.05 Formulary MHS England Ruxolitinib tabs 
11.08.01 Formulary MHS England Serum eye drops severe ocular surface disease
08.02.02 Formulary MHS England Sirolimus tabs, oral solution renal transplant
08.01.05 Formulary MHS England Sorafenib tablets Hepatocellular carcinoma
08.01.05 Formulary MHS England Sorafenib tablets thyroid cancer
08.01.05 Formulary MHS England Sunitinib caps renal cell carcinoma
08.01.05 Formulary MHS England Sunitinib caps gastrointestinal stromal tumours and neuroendocrine tumours
09.01.03 Formulary MHS England Susoctocog alfa injection  
05.03.01 Formulary MHS England Symtuza Darunavir/cobicistat/emtricitabine/tenofovir alafenamide
08.02.02 Formulary MHS England Tacrolimus caps, m/r caps Advagraf®, Prograf® - liver transplant
08.02.02 Formulary MHS England Tacrolimus caps, m/r caps, injection Advagraf®, Prograf®, Adoport® Envarsus®
08.01.05 Formulary MHS England Talimogene laherparepvec injection 
08.01.05 Formulary MHS England Temozolomide caps licensed use
08.02.04 Formulary MHS England Teriflunomide tablets 
03.07 Formulary MHS England Tezacaftor-ivacaftor tabs 
08.02.04 Formulary MHS England Thalidomide caps multiple myeloma
08.01.05 Formulary MHS England Tisagenlecleucel cells dispersion for infusion 
08.01.05 Formulary MHS England Tivozanib caps 
10.01.03 Formulary MHS England Tocilizumab cytokine relsease syndrome following CAR T-cell therapy
10.01.03 Formulary MHS England Tocilizumab injection Adult-Onset Still's Disease
10.01.03 Formulary MHS England Tocilizumab injection Takayasu arteritis -off-label
10.01.03 Formulary MHS England Tocilizumab subcutaneous injection giant cell arteritis
08.01.05 Formulary MHS England Trabectedin injection 
08.01.05 Formulary MHS England Trametinib tabs 
08.01.05 Formulary MHS England Trastuzumab emtansine injection  
08.01.05 Formulary MHS England Trastuzumab injection 
09.08.01 Formulary MHS England Trientine dihydrochloride tabs 
08.01.03 Formulary MHS England Trifluridine–tipiracil tablets 
08.01.05 Formulary MHS England Vemurafenib tabs 
08.01.05 Formulary MHS England Venetoclax tabs 
05.03.03.02 Formulary MHS England Vosevi® tabs sofosbuvir, velpatasvir and voxilaprevir
05.03.03.02 Formulary MHS England Zepatier® tabs elbasvir and grazoprevir
South East London Joint Medicines Formulary